EGFR Mutations and Tyrosine Kinase Inhibitors: Structural Insights and Therapeutic Advances
Megha V. Manoj, Ramesh Babu Mupparaju V, Amrita Thakur, Anil Kumar Sasidharan Pillai
TL;DR
This review discusses how EGFR mutations drive lung cancer and how tyrosine kinase inhibitors work, including challenges with drug resistance and new treatment strategies.
Contribution
The paper offers a structural analysis of EGFR mutations and evaluates new TKIs for overcoming resistance in NSCLC.
Findings
EGFR mutations in the tyrosine kinase domain drive NSCLC progression and treatment resistance.
Secondary mutations and alternative pathways contribute to resistance against tyrosine kinase inhibitors.
New TKIs are being developed to address resistance and improve treatment outcomes.
Abstract
Epidermal Growth Factor Receptor (EGFR) mutations are a major driver of nonsmall cell lung cancer (NSCLC), particularly among nonsmoking populations. Oncogenic mutations within the tyrosine kinase (TK) domain of EGFR play a critical role in activating downstream signaling pathways that promote tumor growth and survival. Targeting this domain has proven effective in developing therapeutic agents for NSCLC. However, treatment with these inhibitors often leads to acquired resistance due to secondary on-target mutations and activation of alternative pathways, making disease management increasingly challenging and necessitating continuous development of novel drugs and strategies. This review provides a comprehensive structural analysis of EGFR, highlighting key activating and resistance-associated mutations and their implications for drug resistance. It also examines mutation-driven…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
Click any figure to enlarge with its caption.
Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6
Figure 7
Figure 8
Figure 9
Figure 10
Figure 11
Figure 12
Figure 13
Figure 14
Figure 15Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsHER2/EGFR in Cancer Research · Lung Cancer Treatments and Mutations · Colorectal Cancer Treatments and Studies